Galiñanes M, Qiu Y, Van Belle H, Hearse D J
Rayne Institute, St Thomas' Hospital, London, United Kingdom.
Cardiovasc Res. 1993 Jan;27(1):90-5. doi: 10.1093/cvr/27.1.90.
The ability of R75231, a nucleoside transport inhibitor, to influence adenine nucleotide metabolism and enhance postischaemic functional recovery was assessed in the blood perfused rabbit heart.
Hearts (n = 8 per group) from donor animals were excised and perfused with blood at 37 degrees C from a support rabbit. After 20 min of aerobic perfusion hearts were arrested with St Thomas' Hospital cardioplegic solution (2 min at 37 degrees C) and rendered globally ischaemic for 60 min. This was followed by 60 min of reperfusion. R75231 (0.1 mg.kg-1, intravenously) was given to donor and support rabbits 1 h before the experiment, control rabbits receiving the same volume of vehicle.
Treatment with R75231 resulted in a 45% reduction in coronary vascular resistance in aerobically perfused control hearts, an effect that was absent during postischaemic reperfusion. Thus, before ischaemia, coronary flow was greater in R75231 treated hearts [6.6(SEM 0.8) ml.min-1] than in controls [4.3(0.6) ml.min-1; p < 0.05] but during reperfusion no significant difference was observed [4.0(0.6) v 3.6(0.3) ml.min-1]. The mean time to onset and extent of contracture during ischaemia was similar in R75231 treated and control groups, at 42(4) v 41(4) min and 27(3) v 26(6) mm Hg, respectively. Left ventricular developed pressure recovered to approximately 50% of its preischaemic value during the first 40 min of reperfusion in both groups; however, after longer durations of reperfusion, it tended to deteriorate in the R75231 treated group whereas it was maintained at a constant level in the controls [37(10) v 53(6) mm Hg, respectively; NS]. At the end of reperfusion, tissue adenosine content was 13-fold greater in the R75231 treated group, at 0.40(0.09) v 0.03(0.01) mumol.g-1 dry wt in controls; p < 0.05; the nucleotide pool, nicotinamide adenine dinucleotide phosphate content, and the energy charge potential were similar in groups.
R75231 decreased coronary vascular resistance and increased coronary flow during aerobic perfusion in control hearts, an effect that was lost after ischaemia and reperfusion. R75231 also increased greatly the tissue content of adenosine but, despite this, failed to improve either the recovery of cardiac contractile function or the replenishment of the adenine nucleotide pool.
在血液灌注的兔心脏中评估核苷转运抑制剂R75231影响腺嘌呤核苷酸代谢及增强缺血后功能恢复的能力。
从供体动物获取心脏(每组n = 8),由一只支持兔提供37℃的血液进行灌注。有氧灌注20分钟后,用圣托马斯医院心脏停搏液使心脏停搏(37℃下2分钟),并使其整体缺血60分钟。随后进行60分钟的再灌注。实验前1小时,给供体兔和支持兔静脉注射R75231(0.1mg·kg-1),对照兔注射相同体积的溶媒。
R75231处理使有氧灌注的对照心脏冠状动脉血管阻力降低45%,缺血后再灌注期间无此效应。因此,在缺血前,R75231处理的心脏冠状动脉血流量[6.6(标准误0.8)ml·min-1]高于对照组[4.3(0.6)ml·min-1;p < 0.05],但再灌注期间未观察到显著差异[4.0(0.6)对3.6(0.3)ml·min-1]。R75231处理组和对照组缺血期间挛缩开始的平均时间和程度相似,分别为42(4)对41(4)分钟和27(3)对26(6)mmHg。两组在再灌注的前40分钟,左心室舒张末压均恢复至缺血前值的约50%;然而,再灌注时间延长后,R75231处理组的左心室舒张末压趋于恶化,而对照组维持在恒定水平[分别为37(10)对53(6)mmHg;无显著性差异]。再灌注结束时,R75231处理组的组织腺苷含量比对照组高13倍,分别为0.40(0.09)对0.03(0.01)μmol·g-1干重;p < 0.05;两组的核苷酸池、烟酰胺腺嘌呤二核苷酸磷酸含量和能量电荷电位相似。
R75231在对照心脏有氧灌注期间降低冠状动脉血管阻力并增加冠状动脉血流量,缺血和再灌注后该效应消失。R75231还使组织腺苷含量大幅增加,但尽管如此,未能改善心脏收缩功能的恢复或腺嘌呤核苷酸池的补充。